These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

220 related articles for article (PubMed ID: 7790944)

  • 1. Iodine-123-IBF SPECT evaluation of extrapyramidal diseases.
    Buck A; Westera G; Sutter M; Albani C; Kung HF; vonSchulthess GK
    J Nucl Med; 1995 Jul; 36(7):1196-200. PubMed ID: 7790944
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [SPECT imaging using [123I]beta-CIT and [123I]IBF in extrapyramidal diseases].
    Sasaki T; Amano T; Hashimoto J; Itoh Y; Muramatsu K; Kubo A; Fukuuchi Y
    No To Shinkei; 2003 Jan; 55(1):57-64. PubMed ID: 12649900
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Dopamine (D2) receptor SPECT with 123I-iodobenzamide (IBZM) in diagnosis of Parkinson syndrome].
    Reiche W; Grundmann M; Huber G
    Radiologe; 1995 Nov; 35(11):838-43. PubMed ID: 8657887
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Iodine-123-epidepride-SPECT: studies in Parkinson's disease, multiple system atrophy and Huntington's disease.
    Pirker W; Asenbaum S; Wenger S; Kornhuber J; Angelberger P; Deecke L; Podreka I; Brücke T
    J Nucl Med; 1997 Nov; 38(11):1711-7. PubMed ID: 9374338
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Comparison of D2 receptor scintigraphy (123I-IBZM) with cerebral perfusion (99m-Tc-HMPAO) in extrapyramidal disorders].
    Saur HB; Bartenstein P; Schober O; Oberwittler C; Lerch H; Masur H
    Nuklearmedizin; 1994 Oct; 33(5):184-8. PubMed ID: 7997375
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Iodine-123 iodobenzofuran (I-123 IBF) SPECT in patients with parkinsonism.
    Nakabeppu O; Nakajo M; Mitsuda M; Tsuchimochi S; Tani A; Osame M
    Ann Nucl Med; 1999 Dec; 13(6):447-52. PubMed ID: 10656283
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Cerebral SPECT with iodine-123 IBZM in patients with extrapyramidal system disorders: the evaluation of its sensitivity in therapy with dopaminergic drugs].
    Hierholzer J; Castelli L; Cordes M; Schelosky L; Poewe W; Felix R
    Radiol Med; 1996 Mar; 91(3):207-10. PubMed ID: 8628932
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Combination of dopamine transporter and D2 receptor SPECT in the diagnostic evaluation of PD, MSA, and PSP.
    Kim YJ; Ichise M; Ballinger JR; Vines D; Erami SS; Tatschida T; Lang AE
    Mov Disord; 2002 Mar; 17(2):303-12. PubMed ID: 11921116
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Lateralized differences in iodine-123-IBZM uptake in the basal ganglia in asymmetric Parkinson's disease.
    Knable MB; Jones DW; Coppola R; Hyde TM; Lee KS; Gorey J; Weinberger DR
    J Nucl Med; 1995 Jul; 36(7):1216-25. PubMed ID: 7790947
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Loss of dopamine-D2 receptor binding sites in Parkinsonian plus syndromes.
    Hierholzer J; Cordes M; Venz S; Schelosky L; Harisch C; Richter W; Keske U; Hosten N; Mäurer J; Poewe W; Felix R
    J Nucl Med; 1998 Jun; 39(6):954-60. PubMed ID: 9627325
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Quantitative analysis of striatal dopamine D2 receptors with 123 I-iodolisuride SPECT in degenerative extrapyramidal diseases.
    Prunier C; Tranquart F; Cottier JP; Giraudeau B; Chalon S; Guilloteau D; De Toffol B; Chossat F; Autret A; Besnard JC; Baulieu JL
    Nucl Med Commun; 2001 Nov; 22(11):1207-14. PubMed ID: 11606886
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Phase 2 clinical study of 123I-IBF, a dopamine D2 receptor imaging agent, to evaluate clinical efficacy and safety in Parkinson's disease and Parkinson syndromes].
    Torizuka K; Mizuno Y; Kubo A; Konishi J; Yonekura Y; Hatazawa J; Momose T; Murata M; Amano T; Fukuyama H; Kuwabara Y
    Kaku Igaku; 1999 Oct; 36(8):845-64. PubMed ID: 10586546
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of striatal dopamine D2 receptors in Parkinson's disease and progressive supranuclear palsy patients using [123I] iodobenzofuran single-photon emission computed tomography.
    Oyanagi C; Katsumi Y; Hanakawa T; Hayashi T; Thuy Dh; Hashikawa K; Nagahama Y; Fukuyama H; Shibasaki H
    J Neuroimaging; 2002 Oct; 12(4):316-24. PubMed ID: 12380478
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of diffusion-weighted imaging and [123I]IBZM-SPECT for the differentiation of patients with the Parkinson variant of multiple system atrophy from those with Parkinson's disease.
    Seppi K; Schocke MF; Donnemiller E; Esterhammer R; Kremser C; Scherfler C; Diem A; Jaschke W; Wenning GK; Poewe W
    Mov Disord; 2004 Dec; 19(12):1438-45. PubMed ID: 15390073
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Multiple system atrophy and progressive supranuclear palsy. Diminished striatal D2 dopamine receptor activity demonstrated by 123I-IBZM single photon emission computed tomography.
    van Royen E; Verhoeff NF; Speelman JD; Wolters EC; Kuiper MA; Janssen AG
    Arch Neurol; 1993 May; 50(5):513-6. PubMed ID: 8489409
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dopamine D2 receptor imaging and measurement with SPECT.
    Brücke T; Wenger S; Asenbaum S; Fertl E; Pfafflmeyer N; Müller C; Podreka I; Angelberger P
    Adv Neurol; 1993; 60():494-500. PubMed ID: 8420177
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Measurement of the dopaminergic degeneration in Parkinson's disease with [123I] beta-CIT and SPECT. Correlation with clinical findings and comparison with multiple system atrophy and progressive supranuclear palsy.
    Brücke T; Asenbaum S; Pirker W; Djamshidian S; Wenger S; Wöber C; Müller C; Podreka I
    J Neural Transm Suppl; 1997; 50():9-24. PubMed ID: 9120429
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Initial experiences with 123-Iodine-IBZM neuroreceptor scintigraphy in extrapyramidal disorders].
    Pávics L; Dibó G; Ambrus E; Séra T; Vécsei L; Csernay L
    Orv Hetil; 2000 May; 141(20):1073-7. PubMed ID: 10851890
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Correlation of clinical response in apomorphine test with D2-receptor status as demonstrated by 123I IBZM-SPECT.
    Schelosky L; Hierholzer J; Wissel J; Cordes M; Poewe W
    Mov Disord; 1993 Oct; 8(4):453-8. PubMed ID: 8232354
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Continuous intravenous infusion of iodine-123-IBZM for SPECT determination of human brain dopamine receptor occupancy by antipsychotic agent RWJ-37796.
    Seibyl JP; Zea-Ponce Y; Brenner L; Baldwin RM; Krystal JH; Offord SJ; Mochoviak S; Charney DS; Hoffer PB; Innis RB
    J Nucl Med; 1996 Jan; 37(1):11-5. PubMed ID: 8543979
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.